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Introduction.
TP63 plays important roles in tumorigenesis, senescence, and epithelial stem cell regulation. It is rarely mutated in human cancers; however, genomic amplification of TP63 is observed in 10% of head and neck squamous cell carcinomas, 13% of serous ovarian carcinomas, 23% of squamous cervical carcinomas and 28% of lung squamous cell carcinomas (1) . TP63 -/-mice exhibit developmental defects, including limb truncations, craniofacial abnormalities, and loss of stratified epithelia (2, 3) . Additional analysis indicates that ΔNp63 isoforms preserve long-term regenerative stasis in epithelial tissues (4) . ΔNp63α is the predominant isoform in normal and malignant breast tissue, and is selectively expressed in the basal/myoepithelial cell layer that houses mammary stem cells (2, 5, 6) . In basal breast cancers and head and neck squamous cell carcinomas (HNSCCs), ΔNp63α confers a survival advantage by actively repressing proapoptotic transcriptional programs (7, 8) . Additionally, ΔNp63α suppresses oncogene-induced senescence, suggesting it plays a role in cancer initiation (9, 10) . These findings implicate
ΔNp63α in cancer initiation and progression and suggest that this gene may be targeted for therapeutic benefit.
Bone morphogenic proteins (BMPs) are members of the TGFβ superfamily of cytokines that regulate diverse cellular processes; including cell-fate specification, embryonicpatterning, and maintenance of developmental potency in embryonic and adult stem cells (11 (12) . Beyond its role in embryonic patterning, BMP signaling preserves prolonged replicative potential of adult stem cells by promoting cellular quiescence (13) (14) (15) . In these studies, BMP signaling ablation caused increased proliferation of stem cell populations (13) (14) (15) .
The role of BMP signaling in breast cancer initiation and progression remains unclear.
Conflicting studies report that BMP signaling exerts either tumor suppressive or tumor promoting effects (16) (17) (18) (19) (20) (21) (22) 
Immunofluorescence.
Following deparaffinization, rehydration, antigen retrieval, and blocking, sections were incubated in primary antibodies overnight at 4°C in a humidified chamber. Primary antibodies used were; p63 (1:100, 4A4 clone, Sigma), P-SMAD1/5/8 (1:100, Cell Signaling), and Vimentin 
Statistical Methods.
Quantitative data is presented as mean values of triplicate points and error bars represent the standard error of the mean (SEM).
Results.
ΔNp63α activates the BMP signaling pathway via enhanced expression of BMP7. Several lines of evidence support a role for BMP signaling in stem cell regulation where it maintains the proliferative potential of adult stem cells (27) . Recent reports demonstrate an interaction between TP63 and BMP signaling. BMP7 expression is lost in TP63 -/-embryos (28), which is consistent with the finding that BMP7 is a transcriptional target of p53 family members, including Supplementary Fig. S4 ). Robust levels of P-SMAD1/5/8 were also noted in tumors from MMTVMyc, MMTV-PyMT, MMTV-Wnt-1, and MMTV-ErbB2/Neu mice relative to normal mammary gland controls (Fig. 2C) . Interestingly, we noted that P-SMAD1/5/8 expression was widespread and not confined to specific cell types within the tumor tissue. This data indicates that BMP signaling is elevated in breast cancer and may be targeted for therapeutic benefit.
Activation of BMP signaling is an early event in breast cancer. There is an urgent need to identify pharmacologically accessible pathways that contribute to early stages of breast cancer.
To address this, clinically defined samples of ductal carcinoma in situ (DCIS) were evaluated for levels of phospho-SMAD1/5/8. Co-staining with p63 revealed increased BMP signaling in luminal epithelial cells within DCIS lesions (Fig. 3A) suggesting that BMP activation may be an early event in breast cancer. This result also suggests a paracrine model in which ΔNp63α promotes BMP7 expression in basal epithelia resulting in activation of BMP signaling in (Fig. 4B ). These effects are dose dependent and evident at doses at which LDN193189 is highly selective for BMP type I receptors (33) . Additionally, LDN193189 potently inhibits colony formation in IMECs (Fig. 4D) CAN-12-2862 mammary epithelial cells (Supplemental Fig. S5C,D) . Conversely, treatment of IMECs with rHBMP7 increased clonogenic capacity (Supplement Fig. S5B ) suggesting that the anticlonogenic effects of LDN193189 are due to disruption of BMP signaling. These data indicate that LDN193189 inhibits stem cell populations and clonogenic capacity in established mammary epithelial cell lines and primary murine tumor cells.
LDN193189 promotes Mesenchymal to Epithelial Transition and restricts plasticity of mammary epithelial cells. EMT is an important cellular process that contributes to metastasis
in response to ionizing radiation and chemotherapeutics (34) suggesting that EMT may represent an adaptive mechanism that enables cells to evade therapeutic assault. The ability of cells to undergo both EMT and the reverse process, Mesenchymal to Epithelial Transition (MET), implies a state of cellular plasticity that may contribute to features of cancer stem cells.
EMT is associated with decreased expression of epithelial cell-adhesion proteins, notably Ecadherin and zonula occludens protein 1 (ZO-1), and a corresponding increase in mesenchymal markers, such as vimentin and N-cadherin. It also renders cells more migratory, invasive, and resistant to apoptosis (34) (35) (36) . The previous data in this study demonstrate that LDN193189 prevents colony formation. During these studies, we noted that LDN193189 causes IMECs to undergo morphological changes that result in colonies that stain more intensely with crystal violet, indicating greater cell density and reduced migratory capacity (Fig. 5A) . Staining of these colonies with ZO-1 revealed that LDN193189 treatment increases ZO-1 expression and promotes tight junction formation (Fig. 5A) . Consistent with this observation, treatment of IMECs with LDN193189 for 72 hours lead to increased expression of the epithelial marker Ecadherin, and a corresponding decrease in expression of the mesenchymal marker, vimentin (Fig. 5B) (Fig. 5C ). The ability of the ALDH1 + fraction to reconstitute the ALDH1 + /ALDH1 -parental culture was accelerated in the presence of LDN193189, which is consistent with previous data demonstrating that LDN193189 reduces the ALDH1 + population (Fig. 5C ). These results indicate that BMP signaling confers plasticity and supports the cancer stem cell state (Fig. 5D ). (Fig. 7B ). Tumors were measured at the time of harvest, and while no group reached statistical significance, LDN193189 treated animals showed a decreased trend in tumor mass for all three cell doses tested (Supplemental Fig. S7B ). The lack of statistical significance is likely attributed to the high variability in tumor mass even within each treatment group. Individual tumor mass data is shown in Supplemental Fig. S7C . Taken together, this data implicate that BMP signaling may be central to regulating epithelial cell plasticity, EMT, and stemness during breast cancer initiation.
LDN193189 exhibits in vivo

Discussion.
Breast cancer is the leading cause of cancer-related death in women worldwide, with incidence rates rising globally over the last 25 years (38) . In the United States, the lifetime risk of breast cancer for all women is 12.7% (38) . Targeted molecular therapies exhibit less toxicity and 
enhanced tumor selectivity than broad-spectrum chemotherapeutics, and have become important components of current breast cancer treatment modalities. Breast cancer progression and recurrence remains a formidable clinical challenge due to acquired resistance to existing therapies, inability to respond to adjuvant therapies, and a failure of drug combinations to produce durable remissions. This highlights the need for the identification of additional genetic alterations that underlie disease recurrence, and subsequent design of selective inhibitors of these pathways for use in novel combination with conventional cytotoxic agents.
Studies presented here evaluate BMP signaling status by measuring the phosphorylation of SMAD1/5/8, which represents a point of convergence for all BMP signaling. We present evidence that BMP signaling is hyper-activated in human and mouse breast tumors relative to normal tissue controls, and that it is highest in the basal breast cancer subtype. Additionally, we present data indicating that activation of BMP signaling is evident in DCIS and in mouse models of pre-malignancy. Furthermore, numerous reports demonstrate a role for BMP signaling in promoting tumor cell migration and invasion (17, (19) (20) (21) (39) (40) (41) , suggesting that BMP signaling may be targeted for therapeutic benefit. In vitro analysis of LDN193189, a small molecule inhibitor of BMPR1 kinases, revealed that suppressing BMP signaling reduced the stem cellenriched ALDH1 + population. Here we show that ΔNp63α can induce BMP7 expression and activate canonical BMP signaling, providing a potential mechanism by which ΔNp63α preserves stem cell proliferative potential. Together our data support the conclusion that BMP signaling may be targeted to reduce the activity of breast cancer stem cells.
In vivo studies revealed that biologically active doses of LDN193189 caused reductions in tumor size and volume in mice treated daily with LDN193189. These effects, however, did not reach statistical significance, which we attribute to the very rapid expansion of tumors in the syngeneic 
